CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

被引：34

作者：

Hellmann, Matthew David

Gettinger, Scott N.

Goldman, Jonathan Wade

Brahmer, Julie R.

Borghaei, Hossein

Chow, Laura Q.

Ready, Neal

Gerber, David E.

Juergens, Rosalyn A.

Shepherd, Frances A.

Laurie, Scott Andrew

Zhou, Ye

Geese, William J.

Agrawal, Shruti

Li, Xuemei

Antonia, Scott Joseph

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Yale Comprehens Canc Ctr, New Haven, CT USA

[3] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[4] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[5] Fox Chase Canc Ctr, Philadelphia, PA USA

[6] Univ Washington, Seattle, WA USA

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA

[9] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[10] Princess Margaret Canc Ctr, Toronto, ON, Canada

[11] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.3001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

3001

引用

页数：2